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The Society for Immunotherapy of Cancer (SITC) 2012 Professional Development Session was held as part of the
SITC 27th Annual Meeting, Washington, DC, on October 24, 2012. The session was designed as a new opportunity
for early career investigators to learn about relevant career development topics in a didactic setting.
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Business of researchBackground
The Society for Immunotherapy of Cancer (SITC) 2012
Professional Development Session was held as part of the
SITC 27th Annual Meeting, Washington, DC, on October
24, 2012. Experts from academia, industry and govern-
ment were available to discuss 3 main topics – obtaining a
K award from the National Institutes of Health (NIH),
preparing for tenure and the business of research. In
addition, the session concluded with a career panel that
outlined opportunities in academia, industry and govern-
ment. With integrated breaks for questions and network-
ing, attendees were also able to closely interact with the
invited experts.
SITC is a non-profit group of medical professionals
established in 1984 to facilitate the exchange and promo-
tion of scientific information about the promise and
breakthroughs of immunotherapy for cancer patients. So-
ciety members include a constituency of nearly 600 clin-
ical and basic scientists from around the world working in
academia, industry, and governmental regulatory agencies.
SITC’s members represent 17 medical specialties and are
engaged in research and treatment of most types of can-
cer. The Society was founded on the belief that new
immune-based treatments would continue to complement
traditional cancer treatments and move into the main-
stream in the fight against cancer. To aid in this effort,
SITC provides a venue to facilitate the discussion of* Correspondence: ccapitini@pediatrics.wisc.edu
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reproduction in any medium, provided the orcurrent clinical trial results and methodologies, as well as
means to collaborate on new initiatives in tumor immun-
ology and cancer immunotherapy with the ultimate goal
of improving cancer patient outcomes.Getting a K99/R00 award from the NIH
Shari Pilon-Thomas, PhD (H. Lee Moffitt) discussed strat-
egies for obtaining the K99/R00 Pathway to Independence
Award (http://grants.nih.gov/grants/guide/pa-files/PA-11-
197.html). This grant is unique in that it offers up to
2 years of mentored research time at the candidate’s insti-
tution (K99 phase), and then the candidate switches to an
independent faculty position at their present, or another,
institution for up to 3 years (R00 phase). It is the only K
award that does not have a U.S. citizenship/permanent
residency requirement. The candidate cannot have com-
pleted more than 5 years of postdoctoral research, have
had a prior K or R level award, or be in an independent re-
search position. The main part of the grant is divided into
a Candidate Information section and a Research Strategy
section. Additional components include a description of
the Research Environment, an Institutional Commitment
letter, letters of support from a mentor and/or co-
mentors, and training in the responsible conduct of
research. Dr. Pilon-Thomas emphasized the importance of
having a strong mentor who is not just a supervisor, but
who is available to help you develop as a scientist and has
a track record of training postdoctoral fellows [1]. She
recommended describing the mentor’s research and how
it both synergizes and differs from the candidate’s pro-
posal. The proposal also needs a means of evaluating thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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summarize how the mentored phase will be important for
the independent phase, and show evidence of long-term
viability. For grants targeted to the National Cancer Insti-
tute, the proposal must include work on human tissues or
human cancers. Thus the K99/R00 is an important mech-
anism for those scientists looking to enter academics, not
only to establish a track record in getting funding, but to
provide a means to have support for mentored training
followed by an independent position.
Getting a K08 award from the NIH
Chris Gamper, MD, PhD (Johns Hopkins University)
presented strategies for getting a K08 Mentored Clinical
Scientist Award (http://grants.nih.gov/grants/guide/pa-
files/PA-11-193.html). This grant offers 3–5 years of
protected salary and supply support as mentored research
time for individuals with clinical doctoral degrees. Candi-
dates must not have had a prior K or R level award, and
cannot be in an independent research position. The crit-
ical components of the application include Candidate In-
formation, a Career Development Plan, Mentor letter, and
a Research Plan. Dr. Gamper recommended stating your
short and long-term career goals, as well as your desire to
be an independent researcher. Importantly, he stated that
the K08 is funding your training, not just your research
plan. He stressed the importance of showing how the can-
didate’s goals are distinct from your mentor’s goals. Dr.
Gamper also recommended taking stock of your deficien-
cies, and how you plan to correct them in your training
plan and outlining how clinical responsibilities will be bal-
anced with the basic research component is also critical.
Regarding the mentor, he thought having an expert in the
same field as the proposed field of study that is accessible
to the candidate and has a track record of mentoring
would be best. A co-mentor may be appropriate, even
from another institution, if they have expertise that com-
plements the primary mentor background in the chosen
field of study. The Research Plan should have 2–4 aims,
and the aims should “stand alone” and not be dependent
on the outcomes of other aims. For resubmissions, re-
spond to all of the reviewers’ comments, consider adding
additional expertise as co-mentors and demonstrate prod-
uctivity since the prior submission [2].
New primary investigators: attracting students and
post-docs, preparing for tenure
Weiping Zou, MD, PhD (University of Michigan)
explained how to build and lead a research team, and
prepare for tenure. He emphasized that success depends
on hiring the right people and keeping them motivated
to empower them to do their best work [3]. Before hir-
ing, the Primary Investigator (PI) must know their own
strengths, their projects, technical skills that they lack,needed level of training in their staff, and the funding
available to support the team. Advertising open positions
both by informal discussion with mentors and colleagues
as well as through conferences and journals is critical.
When hiring, be sure to call references, understand the
candidate’s career goals and make sure the candidate im-
presses you in an interview. As motivation to the team,
Dr. Zou recommends having interesting projects, regular
lab meetings and personal mentoring [1]. He reminded
the group that graduate students and postdocs eventu-
ally become your colleagues, scientific partners and col-
laborators, so treat them well. Regarding preparation for
tenure, he suggested obtaining general information on
the academic pathways at your institution, having a jun-
ior faculty committee with 4–6 senior faculty members,
and listening to recommendations that lead to promo-
tion. The faculty manual should have information re-
garding the average length needed for tenure, promotion
criteria and organizational structure. Dr. Zou empha-
sized that networking both within and outside your in-
stitution is critical, and that success is a combination of
knowing how to focus, obtain funding, work well with
others and balance your time.
The business of research
Lisa Butterfield, PhD (University of Pittsburgh) presented
strategies to leading a successful laboratory. First she
suggested emulating those labs that are successful and
avoiding the pitfalls of labs that are in bad situations. She
recommended becoming an active member of your institu-
tion, including participation in committees, giving seminars
and reviewing grants. Dr. Butterfield suggested applying for
funding from any potential source interested in your re-
search, presenting your data frequently and incorporating
reviewers’ feedback. Regarding grants, she recommended
keeping your CV up-to-date in real time, reading other
successful grants and having someone help you review
comments. Utilizing career training workshops and internal
grant review boards are always helpful. She also re-
commended publishing frequently in as appropriate and
high impact journals as possible, and making sure at least
33% of publication are first or last author. She explained
how hiring talented staff and providing them with a good
work environment will lead to success. Dr. Butterfield
suggested speaking with references by phone before
interviewing staff candidates, and to be the best mentor you
can be by setting clear expectations and acting profession-
ally at all times. She recommended tracking your spending
to stay within budget, but not to be afraid to spend in order
to create more opportunities to earn better grants.
Career panel
Ana Anderson, PhD (Harvard) discussed her career path
into academia, including the challenges of work-life
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mentors. She outlined 5 essential elements for good career
building: commitment, organization, mentorship, infor-
mation and communication. She recommended learning
how to cope with grant/manuscript rejection, working
long hours and weekends. Strategies that help you
organize your work flow, personnel and personal life are
critical. She emphasized the importance of finding a good
mentor, such as someone who is accessible, an advocate
and has a life-long commitment. Dr. Anderson informed
the audience that each institution has information that
outlines criteria for promotion, hiring and grants adminis-
tration. Regarding communication, she recommended giv-
ing oral presentations, writing primary research and
review papers, collaborating and getting feedback from
mentors.
Amy Wesa, PhD (CelSense, Inc) explained which career
paths the PhD biomedical workforce enters after training
is completed, and that about 18% end up in industry, in-
cluding companies that produce drugs, devices or life sci-
ence tools. There are also contract research organizations
that perform discovery, preclinical or clinical studies for a
fee. Within an organization, there are different career lad-
ders that can be navigated, which will vary by work envir-
onment. For example, Celsense, Inc. is a privately held
small biotechnology company offering novel imaging
agents to monitor cells by magnetic resonance imaging.
Working in a small company means employees perform
multiple roles, which can include marketing, fundraising,
research, customer support and regulatory compliance. At
smaller companies, research tends to be on a smaller scale
and customer-driven. She also discussed how they bring
products to market in terms of having good manufactur-
ing practices, quality control studies, preclinical studies
and good laboratory practice studies. Candidates should
be willing to develop their writing skills, be comfortable
giving presentations to scientific and lay audiences, and be
willing to network. The major distinctions from academia
include that everyone in the company is working toward a
common goal, whereas each lab at an academic institution
has different goals. There are not typically students in a
company, there is more team recognition and success is
not defined by publications.
Raj Puri, MD, PhD (Food and Drug Administration)
presented the general organization of the FDA and how
the Center for Biologic Evaluation and Research (CBER)
regulates biological products. He explained that CBER
does conduct some research to stay ahead of the curve as
products and technologies evolve. Since products and
regulatory paradigms constantly evolve, cutting edge re-
search at CBER helps prepare the way for anticipated
products and develop appropriate policy. He discussed the
current research areas as well as types of positions avail-
able in the FDA. Dr. Puri also described the fellowshipsavailable to provide training in regulatory review, inclu-
ding the Interagency Oncology Task Force Fellowship and
the FDA Commissioner’s Fellowship Program. He dis-
cussed the responsibilities of regulatory reviewers and PIs
in product review, policy development, outreach and
research.
Conclusions
The SITC Professional Development Session provided
information relevant to early career scientists looking to
succeed in a career in cancer immunotherapy. Advice
was geared toward graduate, medical and post baccalau-
reate students as well as postdoctoral fellows, clinical
fellows and Assistant Professors. Overriding themes in-
cluded being exceptionally organized and enthusiastic
when preparing a grant application. Identifying a great
mentor was critical both in preparing grants, getting
your first job and in maintaining success as an early car-
eer professional. The field of cancer immunotherapy has
clear opportunities in academia, industry or government,
and knowing how each environment operates is critical
in matching your scientific skills sets with the right car-
eer path.
For more information, the session was recorded and
can be viewed at http://www.sitcancer.org/sitc-meetings/
presentations#.
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